ViroVet NV
Acronym: ViroVet
General Information
Identification Code: 984380024354-62
Website: [object Object]
Entity Form: NV
Registration Category: Companies & groups
Registration Date: 11/7/2016
Last Update: 2/13/2024
EP Accredited Number: 0
Mission & Interests
Goals: ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.
It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.
ViroVet has already enlisted the support of a number of k (...)
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Agriculture and rural development
- Food safety
- Public health
- Research and innovation
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: ViroVet monitores everything linked to viral diseases in livestock and in particular epizootic and zoonotic outbreaks
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Ambachtenlaan 1
Post Code: 3001
City: Heverlee
Country: BELGIUM
Phone: [object Object]
EU Office
Address: Ambachtenlaan 1
Post Code: 3001
City: Heverlee
Country: BELGIUM
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Membership Information
Members10 Percent: 0
Members25 Percent: 2
Members50 Percent: 0
Members75 Percent: 0
Members: 2
Members F T E: 0.5
Info Members: Support for additional work on African Swine Fever and associated stockpiling of emergency-use product to stop and control outbreaks was anticipated, this would increase the working time to at least 3 FTE at 75%. To date the subsidy request to prepare for an ASF outbreak in Europe was denied, new approaches will be considered to continue our work on antiviral agents to block the disease and reduce the impact of a potential outbreak.
Structure
Structure Type: Structure
Is Member Of: none
Organisation Members: FlandersBio (www.flanders.bio) and FlandersVaccines as part of FlandersBio
Leuven Mindgate (www.leuvenmindgate.be)